Commercializing and Business & Corporate Strategy

Mustafa A. Noor, MD, FACP

 

Dr. Noor brings in 18+ years of experience in all phases of clinical development in multiple therapeutic areas with large and small companies.  

Prior to consulting for Kinexum,  Dr. Noor was Chief Development Officer at Akcea Therapeutics in Cambridge, MA and responsible for the integrated activities of Clinical Development and Development Operations teams and focused on a portfolio of antisense oligonucleotides for rare cardiometabolic diseases.  Earlier he was Vice President and therapeutic area head for endocrinology at IPSEN where he oversaw successful submission of sNDA for lanreotide in neuroendocrine tumors and MAA filing for telotristat (Xermelo) for the rare disease of carcinoid syndrome in the EU as part of a strategic collaboration between IPSEN and Lexicon Pharmaceuticals.   Dr. Noor began his career as medical director with BMS in 2001 where he contributed to phase 2 & 3 clinical development of metabolic, cardiovascular and HIV antiviral programs in positions of increasing responsibility leading market differentiation of Reyataz as a lipid and metabolic friendly HIV therapeutic . From 2006 to 2014 he was at GSK and at Pfizer where he served as vice president and clinical head for GSK’s Center of Excellence in External Drug Discovery (CEEDD) and for Pfizer’s Centers for Therapeutic Innovation (CTI) focusing on open innovation, collaboration with biotech and academic partners on a portfolio of multiple programs in early phase trials.

Dr. Noor completed his undergraduate and medical degrees at the University of Chicago and fellowship training in Endocrinology and Metabolism at the University of California, San Francisco.  He is certified in internal medicine and the subspecialty of endocrinology & metabolism by the American Board of Internal Medicine and holds a Master’s Degree in clinical research from Vanderbilt University School of Medicine.